MESO Stock Overview
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$10.82 |
| 52 Week High | AU$12.18 |
| 52 Week Low | AU$1.61 |
| Beta | 2.34 |
| 11 Month Change | 12.12% |
| 3 Month Change | 68.27% |
| 1 Year Change | 303.73% |
| 33 Year Change | -15.20% |
| 5 Year Change | -14.80% |
| Change since IPO | 32.73% |
Recent News & Updates
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Sep 30Mesoblast: Rolling The Dice On Cellular Medicines
Jul 22Recent updates
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Sep 30Mesoblast: Rolling The Dice On Cellular Medicines
Jul 22Mesoblast Limited: Back From The Dead
Apr 10Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Aug 31Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS
Apr 30Mesoblast issues FQ2 operational and financial update
Jan 29Mesoblast's rexlemestrocel-l reduces heart attacks, strokes
Jan 11Mesoblast: The Future Looks Bleak
Dec 24Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events
Dec 15Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%
Dec 02Mesoblast EPS beats by $0.22, misses on revenue
Nov 19Shareholder Returns
| MESO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.6% | -7.5% | -1.2% |
| 1Y | 303.7% | 14.1% | 30.4% |
Return vs Industry: MESO exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: MESO exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| MESO volatility | |
|---|---|
| MESO Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MESO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MESO's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 73 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
Mesoblast Limited Fundamentals Summary
| MESO fundamental statistics | |
|---|---|
| Market cap | US$1.20b |
| Earnings (TTM) | -US$87.96m |
| Revenue (TTM) | US$5.90m |
202.7x
P/S Ratio-13.6x
P/E RatioIs MESO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MESO income statement (TTM) | |
|---|---|
| Revenue | US$5.90m |
| Cost of Revenue | US$41.07m |
| Gross Profit | -US$35.17m |
| Other Expenses | US$52.79m |
| Earnings | -US$87.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.077 |
| Gross Margin | -595.87% |
| Net Profit Margin | -1,490.27% |
| Debt/Equity Ratio | 23.8% |
How did MESO perform over the long term?
See historical performance and comparison